Portal de Periódicos da CAPES

Serum levels of RANKL and OPG, and the RANKL/OPG ratio in bisphosphonate-related osteonecrosis of the jaw: Are they useful biomarkers for the advanced stages of osteonecrosis?

2017; Medicina Oral S.L.; Linguagem: Inglês

10.4317/medoral.22128

1698-6946

Leticia Bagán, Yolanda Jiménez, M Leopoldo, Ana Laura Rubert, José Vicente Bagán Sebastián,

Radiopharmaceutical Chemistry and Applications

Background: We determined whether serum levels of Receptor Activator for Nuclear Factor κ B Ligand (RANKL), Osteoprotegerin (OPG), and the RANKL/OPG ratio could be useful biomarkers for the severity of oral lesions in bisphosphonate-related osteonecrosis of the jaw (BRONJ).Material and Methods: A case-control study in which Group 1 consisted of 41 patients with BRONJ due to bisphosphonates, and Group 2 consisted of 44 healthy control cases.The plasma levels of RANKL and OPG were analyzed by an ELISA assay.The OPG/RANKL ratio was also calculated.We determined if the mean serum values differed among the different stages of BRONJ.Results: Serum levels of RANKL were lower in Group 1 than in Group 2 (p =0.01), and serum levels of OPG were higher in patients with BRONJ than in the controls (p =0.006).The ratio of RANKL/OPG was greater in the controls than in Group 1 (p >0.01).There were no significant differences in the serum levels of RANKL and OPG among the different stages of osteonecrosis (p >0.05).Conclusions: Serum levels of RANKL and OPG, and the RANKL/OPG ratio were not valuable biomarkers for determining the severity of oral lesions in patients with BRONJ.